FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382632314> ?p ?o ?g. }

• W4382632314 abstract "BACKGROUNDIgE-mediated anaphylaxis is a potentially fatal systemic allergic reaction for which there are no currently FDA-approved preventative therapies. Bruton's tyrosine kinase (BTK) is an essential enzyme for IgE-mediated signaling pathways and is an ideal pharmacologic target to prevent allergic reactions. In this open-label trial, we evaluated the safety and efficacy of acalabrutinib, a BTK inhibitor that is FDA approved to treat some B cell malignancies, in preventing clinical reactivity to peanut in adults with peanut allergy.METHODSAfter undergoing graded oral peanut challenge to establish their baseline level of clinical reactivity, 10 patients had a 6-week rest period, then received 4 standard doses of 100 mg acalabrutinib twice daily and underwent repeat food challenge. The primary endpoint was the change in patients' threshold dose of peanut protein to elicit an objective clinical reaction.RESULTSAt baseline, patients tolerated a median of 29 mg of peanut protein before objective clinical reaction. During subsequent food challenge on acalabrutinib, patients' median tolerated dose significantly increased to 4,044 mg (range 444-4,044 mg). 7 patients tolerated the maximum protocol amount (4,044 mg) of peanut protein with no clinical reaction, and the other 3 patients' peanut tolerance increased between 32- and 217-fold. 3 patients experienced a total of 4 adverse events that were considered to be possibly related to acalabrutinib; all events were transient and nonserious.CONCLUSIONAcalabrutinib pretreatment achieved clinically relevant increases in patients' tolerance to their food allergen, thereby supporting the need for larger, placebo-controlled trials.TRIAL REGISTRATIONClinicalTrials.gov NCT05038904FUNDINGAstraZeneca Pharmaceuticals, the Johns Hopkins Institute for Clinical and Translational Research, the Ludwig Family Foundation, and NIH grants AI143965 and AI106043." @default.
• W4382632314 created "2023-07-01" @default.
• W4382632314 creator A5004888276 @default.
• W4382632314 creator A5007359597 @default.
• W4382632314 creator A5045041188 @default.
• W4382632314 creator A5046995526 @default.
• W4382632314 creator A5075754710 @default.
• W4382632314 creator A5080322831 @default.
• W4382632314 creator A5081046119 @default.
• W4382632314 date "2023-08-15" @default.
• W4382632314 modified "2023-10-18" @default.
• W4382632314 title "A phase 2 study of Bruton’s tyrosine kinase inhibition for the prevention of anaphylaxis" @default.
• W4382632314 cites W1994832965 @default.
• W4382632314 cites W2059430155 @default.
• W4382632314 cites W2078941945 @default.
• W4382632314 cites W2086874669 @default.
• W4382632314 cites W2116502370 @default.
• W4382632314 cites W2137821258 @default.
• W4382632314 cites W2154718537 @default.
• W4382632314 cites W2171771895 @default.
• W4382632314 cites W2340183557 @default.
• W4382632314 cites W2598986020 @default.
• W4382632314 cites W2604291868 @default.
• W4382632314 cites W2744715029 @default.
• W4382632314 cites W2750906538 @default.
• W4382632314 cites W2783920282 @default.
• W4382632314 cites W3001375137 @default.
• W4382632314 cites W3012874730 @default.
• W4382632314 cites W3139157067 @default.
• W4382632314 cites W3159691003 @default.
• W4382632314 cites W3192696519 @default.
• W4382632314 cites W4200083379 @default.
• W4382632314 cites W4205262571 @default.
• W4382632314 cites W4206671446 @default.
• W4382632314 cites W4226312459 @default.
• W4382632314 cites W4295138766 @default.
• W4382632314 cites W4311874266 @default.
• W4382632314 cites W4317780658 @default.
• W4382632314 doi "https://doi.org/10.1172/jci172335" @default.
• W4382632314 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37384412" @default.
• W4382632314 hasPublicationYear "2023" @default.
• W4382632314 type Work @default.
• W4382632314 citedByCount "0" @default.
• W4382632314 crossrefType "journal-article" @default.
• W4382632314 hasAuthorship W4382632314A5004888276 @default.
• W4382632314 hasAuthorship W4382632314A5007359597 @default.
• W4382632314 hasAuthorship W4382632314A5045041188 @default.
• W4382632314 hasAuthorship W4382632314A5046995526 @default.
• W4382632314 hasAuthorship W4382632314A5075754710 @default.
• W4382632314 hasAuthorship W4382632314A5080322831 @default.
• W4382632314 hasAuthorship W4382632314A5081046119 @default.
• W4382632314 hasBestOaLocation W43826323141 @default.
• W4382632314 hasConcept C126322002 @default.
• W4382632314 hasConcept C142724271 @default.
• W4382632314 hasConcept C170493617 @default.
• W4382632314 hasConcept C197934379 @default.
• W4382632314 hasConcept C203014093 @default.
• W4382632314 hasConcept C204787440 @default.
• W4382632314 hasConcept C207480886 @default.
• W4382632314 hasConcept C27081682 @default.
• W4382632314 hasConcept C2775933838 @default.
• W4382632314 hasConcept C2776027960 @default.
• W4382632314 hasConcept C2778012357 @default.
• W4382632314 hasConcept C42362537 @default.
• W4382632314 hasConcept C535046627 @default.
• W4382632314 hasConcept C71924100 @default.
• W4382632314 hasConcept C90059517 @default.
• W4382632314 hasConcept C90924648 @default.
• W4382632314 hasConcept C98274493 @default.
• W4382632314 hasConceptScore W4382632314C126322002 @default.
• W4382632314 hasConceptScore W4382632314C142724271 @default.
• W4382632314 hasConceptScore W4382632314C170493617 @default.
• W4382632314 hasConceptScore W4382632314C197934379 @default.
• W4382632314 hasConceptScore W4382632314C203014093 @default.
• W4382632314 hasConceptScore W4382632314C204787440 @default.
• W4382632314 hasConceptScore W4382632314C207480886 @default.
• W4382632314 hasConceptScore W4382632314C27081682 @default.
• W4382632314 hasConceptScore W4382632314C2775933838 @default.
• W4382632314 hasConceptScore W4382632314C2776027960 @default.
• W4382632314 hasConceptScore W4382632314C2778012357 @default.
• W4382632314 hasConceptScore W4382632314C42362537 @default.
• W4382632314 hasConceptScore W4382632314C535046627 @default.
• W4382632314 hasConceptScore W4382632314C71924100 @default.
• W4382632314 hasConceptScore W4382632314C90059517 @default.
• W4382632314 hasConceptScore W4382632314C90924648 @default.
• W4382632314 hasConceptScore W4382632314C98274493 @default.
• W4382632314 hasFunder F4320317924 @default.
• W4382632314 hasFunder F4320332161 @default.
• W4382632314 hasIssue "16" @default.
• W4382632314 hasLocation W43826323141 @default.
• W4382632314 hasLocation W43826323142 @default.
• W4382632314 hasLocation W43826323143 @default.
• W4382632314 hasOpenAccess W4382632314 @default.
• W4382632314 hasPrimaryLocation W43826323141 @default.
• W4382632314 hasRelatedWork W1499041025 @default.
• W4382632314 hasRelatedWork W2030302831 @default.
• W4382632314 hasRelatedWork W2059846063 @default.
• W4382632314 hasRelatedWork W2068603306 @default.
• W4382632314 hasRelatedWork W2087383715 @default.
• W4382632314 hasRelatedWork W2147701903 @default.

• next